Dermal fillers are implantable medical devices injected into the skin to help fill in facial wrinkles, restoring a smoother appearance. In 2018, there were >2,600,000 dermal filling procedures performed in the US, and the market was estimated to reach $10 billion by 2023. Despite the high demand, no dermal filler has been approved by FDA for injection in the superior portion of the face. High blood vessel density around the eye presents the risk for vascular occlusion leading to skin necrosis or blindness. UCLA researchers led by Prof. Timothy Deming and Michael Delong reported a novel dermal filler material, polyion-complex deblock copolypeptide hydrogels (PIC-DCH), which is safer than the currently used hyaluronic acid.
Current point of care diagnostics frequently require blood draws (e.g., blood glucose monitoring for diabetes), hampering our ability to continuously monitor biomarkers such as cortisol and electrolyte levels. Understanding these levels are critical for a range of populations (high-performance athletes, military personnel, the chronically ill). Today, these biomarker analytes can be isolated from sweat with a new platform from FESSwise. The FESSwise platform is capable of broad biomarker monitoring and is pursuing cortisol detection as a first indication. The Freestanding Electrochemical Sensing System (FESS) platform features sweat sampling, electrochemical sensing, and data display / transmission, all within a self-contained wearable platform. The FESS-enabled smartwatch can be used to monitor the metabolite profiles of individuals in sedentary and high-intensity exercise settings.
In orthopaedic surgery, procedures commonly include fixation of bone and soft tissues. Currently, surgical manipulation of these bones and soft tissues is accomplished by the application of manual force either directly on tissue or through devices that transmit forces to the tissue including pins, screws, bolts, straps, and clamps. These methods of performing orthopaedic surgery have several disadvantages: Manual force is limited by the strength and endurance of the surgeon and surgical assistants, manual manipulation has limited precision, reliance on manual manipulation exposes the surgeon and surgical assistants to increased radiation exposure when intra-operative fluoroscopy is used to confirm position during manipulation of bone. ARTS is developing the Robotic Surgical Assist Arm (RSAA), a motorized rigid traction system which standardizes and facilitates the correct placement of the bones. Focusing on long bone repair the initial market would be in the area of 100,000 cases annually in America.